Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AAV is substantially less inflammatory compared with many other viral vectors, treatments may require administration of high vector doses of up to 10 14 vg/ kg, in particular for applications that depend on systemic vector administration.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [11]
Citations
Cites
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., Sylvia, K., Batista, A. R., Artinian, R., Kokoski, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307798 · Cited by 319
Self-citationTracy, S., H�fling, K., Pirruccello, S., Lane, P. H., Reyna, S. M., & Gauntt, C. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200009)62:1<70::aid-jmv11>3.0.co;2-r · Cited by 143
van Velzen, M., Jing, L., Osterhaus, A. D. M. E., Sette, A., Koelle, D. M., & Verjans, G. M. G. M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003547 · Cited by 134
Cahill, M. A., Ernst, W. H., Janknecht, R., & Nordheim, A. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00320-3 · Cited by 69
Cofactor squelching: Artifact or fact?
Schmidt, S. F., Larsen, B. D., Loft, A., & Mandrup, S. (2016) · BioEssays · doi:10.1002/bies.201600034 · Cited by 58
Weuring, W. J., Dilevska, I., Hoekman, J. W., van de Vondervoort, J., Koetsier, M. P., Slot, R. V. ‘., Braun, K. P. J., & Koeleman, B. P. C. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.0013 · Cited by 14
Immune response to the herpes simplex type 1 regulatory proteins ICP8 and VP16 in infected persons
Spatz, M., Wolf, H. M., Thon, V., Gampfer, J., & Eibl, M. M. (2000) · Journal of Medical Virology · Cited by 10
Research works printed but not linked: 1
- 10.1002/1096-9071(200009)62:1<29::aid-jmv5>3.0.co;2-# · doi:10.1002/1096-9071(200009)62:1<29::aid-jmv5>3.0.co;2-#
Cited by
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Epigenetic editing: from concept to clinic
Heller, E. A., Bintu, L., & Rots, M. G. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01323-0 · Cited by 42
Emerging CRISPR Therapies for Precision Gene Editing and Modulation in the Cardiovascular Clinic
Legere, N., & Hinson, J. T. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02125-3 · Cited by 8
The clinical toxicity of advanced therapy medicinal products
Henderson, F. J. H., & Hill, S. L. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70104 · Cited by 6
“79,80 Despite immune suppression, the patient developed ARDS with proinflammatory cytokine release and immune cell recruitment to the lungs.”
The Promise of Epigenetic Editing for Treating Brain Disorders
González-Molina, L. A., Dolga, A. M., Rots, M. G., & Sarno, F. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-75980-2_4 · Cited by 6
Metadata
- Authors
- Lek, A., Keeler, A. M., & Flotte, T. R.
- Affiliations
- Yale University (US)
- University of Massachusetts Chan Medical School (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-07
- Volume
- 389
- Issue
- 23
- Pages
- 2210-2211
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389376244
- Cited by
- 12
- References
- 7
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL158506)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, gene therapy, non-relapse mortality, adverse events, dystrophin
- MeSH terms
- Humans, Patients, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.